earnings
confidence high
sentiment positive
materiality 0.75
Scribe Therapeutics Q2 2026 net loss $6.5M; cash $43M plus $140.6M IPO proceeds fund to H1 2029
Scribe Therapeutics, Inc.
- Q2 net loss $6.5M ($2.62/share) vs $9.9M ($4.08) YoY; collaboration revenue $1.9M vs $4.9M.
- Cash & marketable securities $43.0M at 6/30/26; July IPO + Sanofi placement raised $155.5M gross, $140.6M net.
- Initiated first-in-human Phase 1 of STX-1150 (PCSK9 epigenetic silencing); NHP data showed up to 68% LDL-C reduction.
- Awarded ~$25.7M CIRM grants: $12.7M for STX-1200 (Lp(a)), $13.0M for STX-1400 (triglycerides).
- R&D expenses fell to $8.8M from $13.9M; management expects run-rate funding into H1 2029.